ALK and neoplasm: Patients with lung adenocarcinoma whose tumor harbor specific gene mutations, such as epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) fusion, derive significant benefit from targeted agents, tyrosine kinase inhibitors (TKIs), and have better prognosis [1].